{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:48Z","timestamp":1792597608777,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5\u03b1 receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is characterized by antibody-dependent cell-mediated cytotoxicity activity, giving them specific and rapid anti-IL-5\u03b1 receptor binding abilities and the ability to target a high number of eosinophils in tissues as well as peripheral blood. Recently, reports on the efficacy of benralizumab as a treatment for EGPA have been published, along with reports on some cases that are difficult to treat with existing oral corticosteroids and mepolizumab. Therefore, we focus on the perspective of the efficacy and safety of benralizumab as a treatment for EGPA patients with steroid dependence in this review. A total of 41 patients with EGPA were treated with benralizumab. After the introduction of benralizumab, oral corticosteroids could be reduced to 10\u00a0mg\/day or less in all cases and to less than 5\u00a0mg\/day in 80% or more of the cases. Discontinuation of oral corticosteroids was achieved in more than 40% of patients with EGPA. Benralizumab was effective in patients with mepolizumab-refractory EGPA and intractable cardiac and neuropathy complications. Efficient elimination of eosinophils is expected to improve the remission rate of EGPA with benralizumab treatment. Although the total number of patients was small, benralizumab was safe and tolerable in a wide range of age groups, suggesting efficacy in severe cases with EGPA.<\/jats:p>","DOI":"10.3389\/fphar.2022.865318","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:48:11Z","timestamp":1646916491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yasuhiko","family":"Koga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Aoki-Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kamide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tsurumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakiyo","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.18176\/jiaci.0689","article-title":"Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient with EGPA","volume":"31","author":"Bormioli","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.jaip.2020.01.037","article-title":"An Alternative Approach Against Eosinophils for the Treatment of Eosinophilic Granulomatosis with Polyangiitis","volume":"8","author":"Carrillo-Martin","year":"2020","journal-title":"J. Allergy. Clin. Immunol. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.anai.2020.05.002","article-title":"Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Benralizumab","volume":"125","author":"Chica-Guzm\u00e1n","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.alit.2020.03.001","article-title":"Early Benralizumab for Eosinophilic Myocarditis in Eosinophilic Granulomatosis with Polyangiitis","volume":"69","author":"Colantuono","year":"2020","journal-title":"Allergol. Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"101050","DOI":"10.1016\/j.rmcr.2020.101050","article-title":"Rapid Onset of Effect of Benralizumab on Respiratory Symptoms in a Patient with Eosinophilic Granulomatosis with Polyangiitis","volume":"30","author":"Coppola","year":"2020","journal-title":"Respir. Med. Case. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccm.2016.04.015","article-title":"Eosinophilic Lung Diseases","volume":"37","author":"Cottin","year":"2016","journal-title":"Clin. Chest Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel Mechanisms of Action Contributing to Benralizumab's Potent Anti-eosinophilic Activity","author":"Dagher","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2147\/TCRM.S159949","article-title":"Mepolizumab as the First Targeted Treatment for Eosinophilic Granulomatosis with Polyangiitis: a Review of Current Evidence and Potential Place in Therapy","volume":"14","author":"Faverio","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's Role Remains Uncertain as Anti-interleukin-5 Only Partially Depletes Numbers in Asthmatic Airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on Eosinophilic Granulomatosis with Polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss Syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and Hematological Effects of IL-5(R\u03b1)-targeted Therapy: An Overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/mrcr\/rxab022","article-title":"Rituximab and Mepolizumab Combination Therapy for Glucocorticoid-Resistant Myocarditis Related to Eosinophilic Granulomatosis with Polyangiitis","volume":"6","author":"Higashitani","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/ppul.25286","article-title":"Pulmonary Eosinophilic Vasculitis with Granulomas and Benralizumab in Children","volume":"56","author":"Hinds","year":"2021","journal-title":"Pediatr. Pulmonol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1111\/all.14819","article-title":"Benralizumab Restores Gene and microRNA Expression Involved in Steroid Sensitivity in Severe Asthma","volume":"76","author":"Hirai","year":"2021","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.jaip.2020.04.006","article-title":"Eosinophilic Granulomatosis with Polyangiitis Evolution during Severe Eosinophilic Asthma Treatment with Benralizumab","volume":"8","author":"Ho\u010devar","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.alit.2020.08.005","article-title":"The Effects of Mepolizumab on Peripheral Circulation and Neurological Symptoms in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients","volume":"70","author":"Kitamura","year":"2021","journal-title":"Allergol. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a Humanized anti-IL-5 Receptor Alpha mAb with Enhanced Antibody-dependent Cell-Mediated Cytotoxicity Function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108574","DOI":"10.1016\/j.clim.2020.108574","article-title":"Benralizumab in Eosinophilic Granulomatosis with Polyangiitis Complicated by Staphylococcus aureus Sepsis","volume":"222","author":"Kolios","year":"2021","journal-title":"Clin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of Benralizumab on Airway Eosinophils in Asthmatic Patients with Sputum Eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S401","DOI":"10.1097\/RHU.0000000000001419","article-title":"Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis with Polyangiitis","volume":"27","author":"Lee","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"rkab033","DOI":"10.1093\/rap\/rkab033","article-title":"Emergence of Extrathoracic Manifestations of Eosinophilic Granulomatosis with Polyangiitis during Benralizumab Treatment","volume":"5","author":"Lim","year":"2021","journal-title":"Rheumatol. Adv. Pract."},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12890-021-01397-7","article-title":"Rapid Effect of Benralizumab in Exacerbation of Severe Eosinophilic Asthma Associated with Eosinophilic Granulomatosis with Polyangiitis","volume":"21","author":"Martinez-Rivera","year":"2021","journal-title":"BMC. Pulm. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"212580","DOI":"10.7573\/dic.212580","article-title":"Efficacy and Steroid-Sparing Effect of Benralizumab: Has it an Advantage over its Competitors?","volume":"8","author":"Menzella","year":"2019","journal-title":"Drugs Context"},{"key":"B25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4081\/mrm.2021.779","article-title":"Successful Treatment with Benralizumab in a Patient with Eosinophilic Granulomatosis with Polyangiitis Refractory to Mepolizumab","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/1753465816667659","article-title":"The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma","volume":"10","author":"Menzella","year":"2016","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.18176\/jiaci.0648","article-title":"Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis with Polyangiitis","volume":"31","author":"Miyata","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting Interleukin-5 in Refractory and Relapsing Churg-Strauss Syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The Roles of IL-5 and anti-IL-5 Treatment in Eosinophilic Diseases: Asthma, Eosinophilic Granulomatosis with Polyangiitis, and Eosinophilic Chronic Rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"00451","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-sparing Effects of Benralizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis","volume":"6","author":"Nanzer","year":"2020","journal-title":"ERJ Open Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/24725625.2021.1916159","article-title":"Successful Early Introduction of Mepolizumab for Peripheral Neuropathy with a Peripheral Circulatory Disorder in a Patient with Myeloperoxidase Anti-neutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis with Polyangiitis","volume":"5","author":"Nishihara","year":"2021","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.jaip.2020.05.033","article-title":"Benralizumab as a Glucocorticoid-Sparing Treatment Option for Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis","volume":"8","author":"Padoan","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2102210","DOI":"10.1183\/13993003.02210-2021","article-title":"Benralizumab's Anti-eosinophil Efficacy May Be Decreased by Impaired NK Cell Activity","author":"Poznanski","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.alit.2019.04.006","article-title":"Decrease in MPO-ANCA after Administration of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis","volume":"68","author":"Takenaka","year":"2019","journal-title":"Allergol. Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/BOR.0b013e32834d85ce","article-title":"Churg-Strauss Syndrome: Update on Pathophysiology and Treatment","volume":"24","author":"Vaglio","year":"2012","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.865318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:48:14Z","timestamp":1646916494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.865318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":39,"alternative-id":["10.3389\/fphar.2022.865318"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.865318","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"article-number":"865318"}}